Navigation Links
CV Therapeutics Announces Eight Abstracts Accepted for Presentation at the European Society of Cardiology Congress 2007
Date:8/22/2007

PALO ALTO, Calif., Aug. 22 /PRNewswire-FirstCall/ -- CV Therapeutics, Inc. (Nasdaq: CVTX) announced today that eight abstracts, including a clinical trial update session on anti-arrhythmia data from the MERLIN TIMI-36 study, have been accepted for presentation at the European Society of Cardiology (ESC) Congress 2007 taking place in Vienna, Austria from September 1-5, 2007.

A clinical trial update session entitled, The Effect of Ranolazine, a Novel Anti-anginal Agent with Electrophysiologic Properties, on the Incidence of Tachyarrhythmias: Results from the MERLIN-TIMI 36 Randomized Controlled Trial, is scheduled for presentation Wednesday, September 5 at 9:45 a.m. Central European Summer Time (CEST).

Other accepted abstracts include:

Ranexa(R) (ranolazine extended-release tablets):

Clinical Outcomes in Patients with Diabetes or the Metabolic Syndrome Presenting with Non- ST-elevation Acute Coronary Syndrome in the MERLIN- TIMI 36 Trial; Poster, Sunday, September 2, 8:30 a.m.-12:30 p.m. CEST

Cost of Angina:

Recurrent Angina Following Revascularization - Frequency, Patient Characteristics and Costs; Poster, Wednesday, September 5, 8:30 a.m. - 12:30 p.m. CEST

Late Sodium Current:

Reduction of Repolarization Reserve Unmasks the Role of Late Sodium Current in Rabbit Isolated Hearts; Poster, Sunday, September 2, 8:30 a.m. - 12:30 p.m. CEST

Mechanism of Ranolazine Block of Cardiac Na Channels; Poster, Monday, September 3, 2:00 - 6:00 p.m. CEST

Regadenoson

Results from Two Randomized, Double-blind, Placebo-controlled Trials Evaluating the Safety of Regadenoson in Patients with Reactive Airways Disease; Poster, Tuesday, September 4, 2:00 - 6:00 p.m. CEST

Side Effect Profile and Tolerability of Regadenoson Myocardial Perfusion Scintigraphy in Women; Poster, Tuesday, September 4, 2:00 - 6:00 p.m. CEST

Superior Safety Profile of Regadenoson Versus Adenosine in Patients with Chronic Obstructive Pulmonary Disease Undergoing Radionuclide Myocardial Perfusion Imaging; Poster, Tuesday, September 4, 2:00 - 6:00 p.m. CEST

In addition, on Tuesday, September 4, CV Therapeutics is sponsoring an EBAC (European Board for Accreditation in Cardiology) educational program, Targeting Myocardial Ischaemia-Future Opportunities for Improved Outcomes, chaired by Dr. Phillip Poole-Wilson of the United Kingdom and Dr. Eugene Braunwald of the United States. On Monday, September 3, CV Therapeutics is sponsoring a FOCUS Cardiology Practice Session, Chronic Stable Angina Management.

Additional information regarding the ESC Congress 2007 can be accessed at http://www.escardio.org

About CV Therapeutics

CV Therapeutics, Inc., headquartered in Palo Alto, California, is a biopharmaceutical company focused on applying molecular cardiology to the discovery, development and commercialization of novel, small molecule drugs for the treatment of cardiovascular diseases.

CV Therapeutics' approved product, Ranexa(R) (ranolazine extended-release tablets), is indicated for the treatment of chronic angina in patients who have not achieved an adequate response with other antianginal drugs, and should be used in combination with amlodipine, beta-blockers or nitrates.

CV Therapeutics' clinical and preclinical drug development candidates and programs include regadenoson, which is being developed for potential use as a pharmacologic stress agent in myocardial perfusion imaging studies, and CVT- 6883, which is being developed as a potential treatment for cardiopulmonary diseases. Regadenoson and CVT-6883 have not been determined by any regulatory authorities to be safe or effective in humans for any use.

Except for the historical information contained herein, the matters set forth in this press release are forward-looking statements within the meaning of the "safe harbor" provisions of the Private Securities Litigation Reform Act of 1995. These forward-looking statements are subject to risks and uncertainties that may cause actual results to differ materially, including operating losses and fluctuations in operating results; capital requirements; regulatory review and approval of our products; special protocol assessment agreement; the conduct and timing of clinical trials; commercialization of products; market acceptance of products; product labeling; concentrated customer base; and other risks detailed from time to time in CV Therapeutics' SEC reports, including its Quarterly Report on Form 10-Q for the quarter ended June 30, 2007. CV Therapeutics disclaims any intent or obligation to update these forward-looking statements.


'/>"/>
SOURCE CV Therapeutics, Inc.
Copyright©2007 PR Newswire.
All rights reserved

Related medicine technology :

1. Cell Therapeutics, Inc. Management to Discuss Todays Announcement of Interim Pixantrone Study Results
2. Halozyme Therapeutics Enhanze Technology Large Protein Molecule Therapeutic Clinical Trial Results Presented at the 34th Annual Meeting of the Controlled Release Society
3. CV Therapeutics Identifies Potential Anti-Diabetic Mechanism of Action for Ranexa
4. GTC Biotherapeutics to Webcast Corporate Presentation at the C.E. Unterberg, Towbin Emerging Growth Life Opportunities Conference
5. Fat Kills Cancer: Turning Stem Cells from Fat Tissue into Personalized, Cancer-Targeted Therapeutics
6. A 4-Week Therapy with Transition Therapeutics E1-I.N.T. Leads to Sustained Reductions in Blood Glucose Levels for 6 Months Post-treatment in Type 2 Diabetes Patients
7. Clinical Trial Suggests Bone Marrow Stem Cells Are Useful for Spinal Cord Injury; PrimeCell Therapeutics Provided Pre-Clinical Study
8. Pieris Progresses Development of its Proprietary Biotherapeutics Platform: Successful Demonstration of Dual Targeting With Duocalin(R) Technology
9. Opexa Therapeutics Reports Positive Top-line Data in Phase I/II Extension Trial with Tovaxin for Multiple Sclerosis
10. Orexigen Therapeutics to Present Data on Contrave Impact on Visceral Fat and Insulin Resistance at American Diabetes Association 67th Scientific Sessions in Chicago June 23
11. Allos Therapeutics Reports Results for Phase 3 Enrich Study of Efaproxyn in Women With Brain Metastases Originating From Breast Cancer
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/24/2016)... 2016 Research and Markets has announced ... Diagnostic Tests" report to their offering. ... The World Market for Companion Diagnostics covers ... Market analysis in the report includes the following: ... Diagnostic Kits) by Region (N. America, EU, ROW), 2015-2020 ...
(Date:6/24/2016)... , Belgium , June 24, ... VNRX), today announced the appointment of Dr. ... Directors as a Non-Executive Director, effective June 23, ... Audit, Compensation and Nominations and Governance Committees.  As ... Futcher will provide independent expertise and strategic counsel ...
(Date:6/23/2016)... Research and Markets has announced the addition of the ... report to their offering. ... failure, it replaces the function of kidneys by removing the ... the treatment helps to keep the patient body,s electrolytes such ... Increasing number of ESRD patients & substantial healthcare expenditure on ...
Breaking Medicine Technology:
(Date:6/27/2016)... ... June 27, 2016 , ... TopConsumerReviews.com recently awarded their highest five-star ... , Millions of individuals in the United States and Canada wear eyeglasses. Once considered ... both correct vision and make a fashion statement. Even celebrities use glasses as a ...
(Date:6/26/2016)... ... ... Pixel Film Studios Released ProSlice Levels, a Media Slicing Effect Plugin ... whole new perspective by using the title layers in ProSlice Levels to split-up ... Levels contains over 30 Different presets to choose from. FCPX users can ...
(Date:6/26/2016)... ... June 26, 2016 , ... Many women are confused ... endometriosis. These women need a treatment plan to not only alleviate symptoms and ... help for preservation of fertility and ultimately achieving a pregnancy. The specialists at ...
(Date:6/25/2016)... Miami, FL (PRWEB) , ... June 25, 2016 , ... The temporary closing of Bruton ... Plant City Observer , brings up a new, often overlooked aspect of head lice: ... The closing for fumigation is not a common occurrence, but a necessary one in the ...
(Date:6/25/2016)... ... 25, 2016 , ... As a lifelong Southern Californian, Dr. Omkar Marathe earned ... the David Geffen School of Medicine at UCLA. He trained in Internal Medicine at ... fellowship in hematology/oncology at the UCLA-Olive View-Cedars Sinai program where he had the opportunity ...
Breaking Medicine News(10 mins):